SCHEMBL2929922

SCHEMBL2929922

CCN(CC)CCn1ncc2c(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc21

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.47
MAPK13 O15264 5/20 0.47
MAPK12 P53778 5/20 0.47
MAPK11 Q15759 5/20 0.47
CSNK1E P49674 3/20 0.37
CSNK1D P48730 2/20 0.37
CSNK1A1 P48729 1/20 0.37
KMT2A Q03164 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652680 0.88 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL2929824 0.86 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL2926671 0.85 ALOX5 (0.42) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL2930799 0.84 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL2930582 0.83 SIGMAR1 (0.41) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL2931824 0.82 CSNK1D (0.48) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL1386735 0.80 CYP17A1 (0.44) MAPK14MAPK13MAPK12MAPK11CSNK1E
SCHEMBL2925197 0.80 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11
SCHEMBL2927923 0.80 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11SIGMAR1
SCHEMBL2930745 0.80 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK13 36/4885MAPK12 38/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.